By Adriano Marchese
Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents.
The U.S. District Court of Massachusetts ruled that Pfizer's motion that U.S. Patent Number 11,358,953 is invalid, Enanta said Tuesday.
Through a patent infringement lawsuit, the clinical-stage biotechnology was seeking damages for infringement of the patent in the manufacture, use and sale of Pfizer's Paxlovid.
The court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity.
"Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit," it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 24, 2024 07:24 ET (12:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。